Novel factor X deficiency. Normal partial thromboplastin time and associated spindle cell thymoma

1985 ◽  
Vol 79 (1) ◽  
pp. 122-126 ◽  
Author(s):  
Richard E. Nora ◽  
William R. Bell ◽  
Dennis A. Noe ◽  
Pam W. Sholar
PEDIATRICS ◽  
1972 ◽  
Vol 49 (2) ◽  
pp. 316-316
Author(s):  
William E. Hathaway

Several discrepancies in the description of the coagulation data presented in the article by Schiller and others1 are apparent. A patient with "definite" Factor X deficiency of a clinically severe degree should have an abnormal prothrombin time and thromboplastin generation test. The authors report these tests to be within normal limits. Also, a platelet adhesiveness of 74% is hardly "slightly reduced" by most published normal values which range from 20 to 80%. In addition, if "A.P.T.T." means "a partial thromboplastin time," then this test should also be abnormal.


1974 ◽  
Vol 31 (01) ◽  
pp. 040-051 ◽  
Author(s):  
Gustav Gaudernack ◽  
Åse Gladhaug Berre ◽  
Bjarne Østerud ◽  
Hans Prydz

SummaryMonospecific antisera against the human coagulation factor X have been raised in rabbits by injections of purified antigen. Such antiserum was used to study the cross-reacting material without factor X activity which is present in the blood of warfarin-treated patients and animals as well as to study the changes in factor X during coagulation. One patient with congenital factor X deficiency was also studied.A complete identity was found between factor X in Macaca mulatta and human blood. During warfarin treatment antigenically cross-reacting material appeared in plasma. This was not adsorbed on BaSO4, and inhibited the coagulation activity of normal factor X.Both this material, normal factor X and the cross-reacting material in plasma from a patient congenitally deficient in factor X gave rise to split products during coagulation by the intrinsic pathway, i. e. all of them served as substrates for the intrinsic activator of factor X.


Author(s):  
Antonio Girolami ◽  
Diana Noemi Garcia de Paoletti ◽  
Marcelo Leonardo Nenkies ◽  
Silvia Ferrari ◽  
Hugo Guglielmone

Background: Investigation of rare bleeding disorders in Latin-America. Objective: The report of a new case of FX deficiency due to a compound heterozygosis. Methods: Accepted clotting procedures were used. Sequencing of DNA was carried out by means of Applied Biosystems Instruments. Results: A compound heterozygote due to the association of a new mutation (Gla72Asp) with an already known mutation (Gly154Arg) of the FX gene is reported. The proposita is a 38 year old female who had a moderate bleeding tendency (menorrhagia, epistaxis, easy bruising). The proposita has never received substitution therapy but in the occasion of a uterine biopsy. The mother was asymptomatic but was a heterozygote for the new mutation. The father was asymptomatic but had deserted the family and could not be investigated. After this abandonment the mother of the proposita re-married with an asymptomatic man and she gave birth to a son who was asymptomatic but was also heterozygous for the new mutation (Gla72Asp). As a consequence it has to be assumed that the first husband of the mother of the proposita was heterozygous for the known mutation (Gly154Arg). Conclusion: This is the third case of a new mutation in the FX gene reported, during the past few years, in Argentina.


2011 ◽  
Vol 4 (2) ◽  
pp. 101-103
Author(s):  
R. Raina ◽  
V. Nadig ◽  
D. Patel ◽  
A. Jegalian ◽  
B. Silver ◽  
...  

2001 ◽  
Vol 73 (3) ◽  
pp. 390-392 ◽  
Author(s):  
Eriko Morishita ◽  
Kazuo Yamaguchi ◽  
Hidesaku Asakura ◽  
Masanori Saito ◽  
Masahide Yamazaki ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document